The European Commission has not yet secured the 300 million corona vaccines from pharmaceuticals Pfizer and BioNTech destined for Europe.
As early as early September, the executive board of the EU concluded “exploratory talks” about the delivery of 200 million doses if the vaccine proved safe and effective, with an option for an additional 100 million doses.
A signature on a final purchase contract still has to be put, a spokesperson confirms.
On Monday it was announced that the corona vaccine from pharmaceuticals Pfizer and BioNTech is 90 percent effective in preventing infection, according to preliminary research results.
Brussels negotiates and buys vaccines on behalf of the EU, which are allocated to the member states according to a specific distribution key.
The contract with the commission will be signed shortly, said responsible European Commissioner Stella Kyriakides on Monday.
However, the committee has already signed sales contracts for Covid-19 vaccines with AstraZeneca (300 million doses), Sanofi-GSK (300 million) and Johnson & Johnson (200 million).